Focus on Anemia, Suspect MDS:

A pocket guide to diagnosing MDS

Symptoms of MDS

Typical presenting symptoms of MDS are generally non-specific and usually differs, depending on the type of cytopenia^{1,2}

Most common symptoms of MDS

Anemia¹

- Fatigue/weakness
- Shortness of breath
 - Pale skin Chest pains
- Loss of appetite Cold extremities

Palpitations

Neutropenia¹

- Frequent infections Fever
 - Mouth sores

Thrombocytopenia¹

- Easy bruising
- Prolonged
- bleeding
- Petechiae

Criteria for MDS diagnosis

An International Working Group has recommended a diagnostic guideline to assist in providing consistent diagnosis of MDS³

Minimal prerequisites to establish MDS diagnosis^{3,4}

 \geq 1 unexplained cytopenia

Exclusion of other potential disorders as primary reason for dysplasia/cytopenia

- The diagnosis of MDS also requires \geq 1 of the following³:
- 1. \geq 10% morphologic dysplasia in \geq 1 of the 3 lineages of hematopoietic cells


Other symptoms of MDS

- 2. A blast cell count of 5%-19%
- 3. A specific MDS-associated karyotype such as del(5q), del(20q), +8, or -7/del(7q)

Diagnosing MDS

There is no single diagnostic parameter for MDS; therefore, diagnosis requires a combination of clinical suspicion, laboratory tests, morphologic analysis, and cytogenetic/molecular evaluation⁴⁻⁶

Diagnostic workup for MDS^{6,7}



Learn more at SpotlightOnAnemia.com



Focus on Anemia, Suspect MDS:

A pocket guide to diagnosing MDS

Classification

Two updated classifications for MDS were developed in 2022: the WHO5 and the ICC for Myeloid Neoplasms and Acute Leukemia, which are overall similar but with some differences in diagnostic criteria and nomenclature^{6,8}

Comparison of MDS classification according to WHO5 and ICC^{6,8-10}

Bone marrow blasts	WHO5	ICC			
No dysplasia	CCUS	CCUS/MDS-NOS without dysplasia			
< 5%	MDS, hypoplastic	Not included			
	MDS with LB	MDS-NOS with SLD, or with MLD			
	MDS with LB and isolated 5q deletion	MDS with del(5q)			
	MDS with LB and <i>SF3B1</i> mutation ^a	MDS with mutated SF3B1			
5%-9%	MDS with IB1	MDS with EB			
	MDS with fibrosis ^b	Not included			
10%-19%	MDS with IB2	MDS/AML			
	MDS with biallelic <i>TP53</i> inactivation ^c	MDS with mutated <i>TP53</i> ^d MDS/AML with mutated <i>TP53</i> ^e			

^aDetection of \geq 15% ring sideroblasts may substitute for *SF3B1* mutation. Acceptable related terminology: MDS with low blasts and ring sideroblasts. ^bBone marrow blasts: 5%-19%. ^cBone marrow blasts: 0%-9%. ^cBone marrow blasts: 10%-19%.

Adapted with permission from Blood.6

Risk stratification

The IPSS-R is the most commonly used risk stratification system in MDS, taking into account the degree of cytopenia, proportion of blasts in the bone marrow, and presence of cytogenetic abnormalities^{2,11,12}

Revised International Prognostic Scoring System (IPSS-R)¹¹

Recently, the IPSS-M was developed, which integrated information from 31 gene mutations in addition to the IPSS-R components $^{2,12,13}\,$

Molecular International Prognostic Scoring System (IPSS-M)¹³

Very low (≤ 1.5)	Low (> 1.5 to 3)	Intermediate (> 3 to 4.5)	High (> 4.5 to 6)	Very high (> 6)	Very low (≤ −1.5)	Low (> -1.5 to -0.5)	Moderate low (> -0.5 to 0)	high	High (> 0.5 to 1.5)	Very high (> 1.5)
19%	38%	20%	13%	10%	14%	33%	11%	11%	14%	17%
8.8	5.3	3.0	1.6	0.8	10.6	6.0	4.6	2.8	1.7	1.0
Median survival, years				Median survival, years						

≈ 77% of patients are diagnosed with lower-risk MDS

CCUS, clonal cytopenia of unknown significance; del, deletion; EB, excess blasts; FISH, fluorescence in situ hybridization; GI, gastrointestinal; IB, increased blasts; ICC, International Consensus Classification; IPSS-M, Molecular International Prognostic Scoring System; IPSS-R, Revised International Prognostic Scoring System; ITP, idiopathic thrombocytopenic purpura; LB, low blasts; MDS, myelodysplastic syndromes; MDS/AML, myelodysplastic syndromes/acute myeloid leukemia overlap; MDS-NOS, myelodysplastic syndrome-not otherwise specified; MLD, multilineage dysplasia; SLD, single-lineage dysplasia; WHOS, World Health Organization 5th edition.

References: 1. Referenced with permission from the NCCN Guidelines for Patients[®] for Myelodysplastic Syndromes, 2021. © National Comprehensive Cancer Network, Inc. 2021. All rights reserved. Accessed May 31, 2024. To view the most recent and complete version of the NCCN Guidelines for Patients, go online to <u>NCCN.org/patientguidelines</u> 2. Sekeres MA, Taylor J. JAMA. 2022;328:872-880. 3. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines[®]) for Myelodysplastic Syndromes V.2.2024. © National Comprehensive Cancer Network, Inc. 2024. All rights reserved. Accessed May 30, 2024. To view the most recent and complete version of the guidelines of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way. 4. Weinberg OK, Hasserjian RP. Semin Hematol. 2019;56:15-21. 5. Barone P, Patel S. Semin Diagn Pathol. 2023;40:172-181. 6. Hasserjian RP et al. *Blood*. 2023;142:2247-2257. 7. Foran JM, Shammo JM. Am J Med. 2012;125(suppl):S6-S13. 8. Xu ML, Hasserjian RP. *Cancer J*. 2023;29:122-129. 9. Arber DA et al. *Blood*. 2022;140:1200-1228. 10. Khoury JD et al. *Leukemia*. 2022;36:1703-1719. 11. Greenberg PL et al. *Blood*. 2012;120:2454-2465. 12. Volpe VO et al. *Clin Lymphoma Myeloma Leuk*. 2023;23:168-177. 13. Bernard E et al. *NEJM Evid*. 2022;1. doi:10.1056/EVIDoa2200008.



